Do you want to read an article? Please log in or register.
Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
Myocardial Infarction
Related content
RECOMMENDED
Lipid-Lowering Drugs
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
doi: 10.1001/jamacardio.2020.0882.
Heart, Artery and Coronary DiseasesMyocardial Infarction
Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial
JAMA Cardiol.
Olivier CB, Mulder H, Hiatt WR, Jones WS, Fowkes FGR, Rockhold FW, Berger JS, Baumgartner I, Held P, Katona BG, Norgren L, Blomster J, Patel MR, Mahaffey KW
doi: 10.1001/jamacardio.
Myocardial Infarction
The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction.
Am Heart J.
Hennessy T, Soh L, Bowman M, Kurup R, Schultz C, Patel S, Hillis GS
doi: 10.1016/j.ahj.
Heart, Artery and Coronary DiseasesMyocardial Infarction
Timing of Angiography and Outcomes in High-Risk Patients with Non-ST Segment Elevation Myocardial Infarction Managed Invasively: Insights from the TAO Trial
Circulation.
Deharo P, Ducrocq G, Bode C, Cohen M, Cuisset T, Mehta S, Pollack CV Jr, Wiviott SD, Elbez Y, Sabatine M, Steg PG
doi: 10.1161/
Myocardial Infarction
Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial
J Am Heart Assoc.
Gencer B, Li XS, Gurmu Y, Bonaca MP, Morrow DA, Cohen M, Bhatt DL, Steg PG, Storey RF, Johanson P, Wang Z, Hazen SL, Sabatine MS
doi: 10.1161/JAHA.119.015331.
Myocardial InfarctionTherapy and Intervention
Impact of Sex and Contact-to-Device Time on Clinical Outcomes in Acute ST-Segment Elevation Myocardial Infarction-Findings From the National Cardiovascular Data Registry.
J Am Heart Assoc.
Roswell RO, Kunkes J, Chen AY, Chiswell K, Iqbal S, Roe MT, Bangalore S
doi: 10.1161/JAHA.116.004521.
Myocardial Infarction
16-year follow-up of the Danish Acute Myocardial Infarction 2 (DANAMI-2) trial: primary percutaneous coronary intervention vs. fibrinolysis in ST-segment elevation myocardial infarction
Eur Heart J.
Thrane PG, Kristensen SD, Olesen KKW, Mortensen LS, Bøtker HE, Thuesen L, Hansen HS, Abildgaard U, Engstrøm T, Andersen HR, Maeng M
doi: 10.1093/eurheartj/ehz595.
Cardiovascular Risk and Diseases
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial
Eur Heart J.
Fitchett D, Inzucchi SE, Wanner C, Mattheus M, George JT, Vedin O, Zinman B, Johansen OE
doi: 10.1093/eurheartj/ehz621.
Myocardial InfarctionTherapy and Intervention
Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-segment elevation myocardial infarction: the FAST-MI programme
Eur Heart J.
Danchin N, Popovic B, Puymirat E, Goldstein P, Belle L, Cayla G, Roubille F, Lemesle G, Ferrières J, Schiele F, Simon T, FAST-MI Investigators.
doi: 10.1093/eurheartj/ehz665.